Clinical Trial Detail

NCT ID NCT01067469
Title Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

glioblastoma multiforme

Therapies

Bevacizumab

Bevacizumab + Lomustine

Age Groups: adult

No variant requirements are available.